[G26-21] Atidarsagene autotemcel OTL-200 (metachromatic leukodystrophy) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V
Last updated 23.09.2026
Project no.:
G26-21
Commission:
Commission awarded on 30.06.2026 by the Federal Joint Committee (GBA).
Report type:
Dossier assessment
Status:
Commission work started
Department/Division:
Health Economics
Topic:
Digestion, metabolism and hormones
Note:
In accordance with §35a (1) Sentence 11 Social Code Book (SGB) V, the added medical benefit of orphan drugs is deemed as proven by the fact that they have been approved. On behalf of the Federal Joint Committee (GBA), IQWiG therefore solely assesses the information on patient numbers and costs in the pharmaceutical company's dossier.
| Project no. | Title | Status |
|---|---|---|
| G21-16 | Atidarsagene autotemcel/OTL-200 (metachromatic leukodystrophy) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V | Commission completed |